Tanaka Kenichi A, Key Nigel S, Levy Jerrold H
Department of Anesthesiology, Division of Cardiothoracic Anesthesia, Emory University School of Medicine, Atlanta, GA 30322, USA.
Anesth Analg. 2009 May;108(5):1433-46. doi: 10.1213/ane.0b013e31819bcc9c.
Perioperative bleeding is a major challenge particularly because of increasing clinical use of potent antithrombotic drugs. Understanding current concepts of coagulation is important in determining the preoperative bleeding risk of patients, and in managing hemostatic therapy perioperatively. The serine protease thrombin plays pivotal roles in the activation of additional serine protease zymogens (inactive enzymatic precursors), cofactors, and cell-surface receptors. Thrombin generation is closely regulated to locally achieve rapid hemostasis after injury without causing uncontrolled systemic thrombosis. During surgery, there are major disturbances in coagulation and inflammatory systems because of hemorrhage/hemodilution, blood transfusion, and surgical stresses. Postoperative bleeding often requires allogeneic blood transfusions, which support thrombin generation and hemostasis. However, procoagulant activity and inflammation are increased postoperatively; thus, antithrombotic therapy may be required to prevent perioperative thrombotic complications. There have been significant advances in the management of perioperative hemostasis and thrombosis because of the introduction of novel hemostatic and antithrombotic drugs. However, a limitation of current treatment is that conventional clotting tests do not reflect the entire physiological processes of coagulation making optimal pharmacologic therapy difficult. Understanding the in vivo regulatory mechanisms and pharmacologic modulation of thrombin generation may help control bleeding without potentially increasing prothrombotic risks. In this review, we focus on the regulatory mechanisms of hemostasis and thrombin generation using multiple, simplified models of coagulation.
围手术期出血是一项重大挑战,尤其是考虑到强效抗血栓药物在临床上的使用日益增加。了解当前的凝血概念对于确定患者术前出血风险以及围手术期止血治疗的管理至关重要。丝氨酸蛋白酶凝血酶在激活其他丝氨酸蛋白酶原(无活性酶前体)、辅因子和细胞表面受体方面发挥着关键作用。凝血酶的生成受到严格调控,以在损伤后局部迅速实现止血,同时又不会导致不受控制的全身血栓形成。在手术过程中,由于出血/血液稀释、输血和手术应激,凝血和炎症系统会出现重大紊乱。术后出血通常需要输注异体血,这有助于凝血酶生成和止血。然而,术后促凝活性和炎症会增加;因此,可能需要抗血栓治疗以预防围手术期血栓形成并发症。由于新型止血和抗血栓药物的引入,围手术期止血和血栓形成的管理取得了重大进展。然而,当前治疗的一个局限性在于传统凝血试验无法反映凝血的整个生理过程,这使得优化药物治疗变得困难。了解凝血酶生成的体内调节机制和药物调节可能有助于控制出血,同时又不会潜在增加血栓形成风险。在本综述中,我们使用多种简化的凝血模型重点关注止血和凝血酶生成的调节机制。